Literature DB >> 17693596

Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates.

Alix Coste1, Anna Selmecki, Anja Forche, Dorothée Diogo, Marie-Elisabeth Bougnoux, Christophe d'Enfert, Judith Berman, Dominique Sanglard.   

Abstract

TAC1 (for transcriptional activator of CDR genes) is critical for the upregulation of the ABC transporters CDR1 and CDR2, which mediate azole resistance in Candida albicans. While a wild-type TAC1 allele drives high expression of CDR1/2 in response to inducers, we showed previously that TAC1 can be hyperactive by a gain-of-function (GOF) point mutation responsible for constitutive high expression of CDR1/2. High azole resistance levels are achieved when C. albicans carries hyperactive alleles only as a consequence of loss of heterozygosity (LOH) at the TAC1 locus on chromosome 5 (Chr 5), which is linked to the mating-type-like (MTL) locus. Both are located on the Chr 5 left arm along with ERG11 (target of azoles). In this work, five groups of related isolates containing azole-susceptible and -resistant strains were analyzed for the TAC1 and ERG11 alleles and for Chr 5 alterations. While recovered ERG11 alleles contained known mutations, 17 new TAC1 alleles were isolated, including 7 hyperactive alleles with five separate new GOF mutations. Single-nucleotide-polymorphism analysis of Chr 5 revealed that azole-resistant strains acquired TAC1 hyperactive alleles and, in most cases, ERG11 mutant alleles by LOH events not systematically including the MTL locus. TAC1 LOH resulted from mitotic recombination of the left arm of Chr 5, gene conversion within the TAC1 locus, or the loss and reduplication of the entire Chr 5. In one case, two independent TAC1 hyperactive alleles were acquired. Comparative genome hybridization and karyotype analysis revealed the presence of isochromosome 5L [i(5L)] in two azole-resistant strains. i(5L) leads to increased copy numbers of azole resistance genes present on the left arm of Chr 5, among them TAC1 and ERG11. Our work shows that azole resistance was due not only to the presence of specific mutations in azole resistance genes (at least ERG11 and TAC1) but also to their increase in copy number by LOH and to the addition of extra Chr 5 copies. With the combination of these different modifications, sophisticated genotypes were obtained. The development of azole resistance in C. albicans is therefore a powerful instrument for generating genetic diversity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693596      PMCID: PMC2043391          DOI: 10.1128/EC.00151-07

Source DB:  PubMed          Journal:  Eukaryot Cell        ISSN: 1535-9786


  57 in total

Review 1.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Effect of the major repeat sequence on mitotic recombination in Candida albicans.

Authors:  Paul R Lephart; Paul T Magee
Journal:  Genetics       Date:  2006-10-08       Impact factor: 4.562

3.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

4.  A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans.

Authors:  Alix Coste; Vincent Turner; Françoise Ischer; Joachim Morschhäuser; Anja Forche; Anna Selmecki; Judith Berman; Jacques Bille; Dominique Sanglard
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

5.  Upc2p and Ecm22p, dual regulators of sterol biosynthesis in Saccharomyces cerevisiae.

Authors:  J Rine
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

6.  Clustered amino acid substitutions in the yeast transcription regulator Pdr3p increase pleiotropic drug resistance and identify a new central regulatory domain.

Authors:  A Nourani; D Papajova; A Delahodde; C Jacq; J Subik
Journal:  Mol Gen Genet       Date:  1997-10

7.  Transcriptional activation domains of the Candida albicans Gcn4p and Gal4p homologs.

Authors:  Mikhail Martchenko; Anastasia Levitin; Malcolm Whiteway
Journal:  Eukaryot Cell       Date:  2006-12-08

8.  Evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; D Sanglard; D Calabrese; C Sirjusingh; J B Anderson; L M Kohn
Journal:  J Bacteriol       Date:  2000-03       Impact factor: 3.490

Review 9.  Resistance of human fungal pathogens to antifungal drugs.

Authors:  Dominique Sanglard
Journal:  Curr Opin Microbiol       Date:  2002-08       Impact factor: 7.934

10.  Shuttle vectors for Candida albicans: control of plasmid copy number and elevated expression of cloned genes.

Authors:  Wenjin Du; Melisa Coaker; Jack D Sobel; Robert A Akins
Journal:  Curr Genet       Date:  2004-03-18       Impact factor: 3.886

View more
  131 in total

1.  Loss of heterozygosity at an unlinked genomic locus is responsible for the phenotype of a Candida albicans sap4Δ sap5Δ sap6Δ mutant.

Authors:  Nico Dunkel; Joachim Morschhäuser
Journal:  Eukaryot Cell       Date:  2010-11-19

2.  Rad52 function prevents chromosome loss and truncation in Candida albicans.

Authors:  E Andaluz; A Bellido; J Gómez-Raja; A Selmecki; K Bouchonville; R Calderone; J Berman; G Larriba
Journal:  Mol Microbiol       Date:  2011-01-27       Impact factor: 3.501

3.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 5.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

6.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

7.  Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system.

Authors:  Alix T Coste; Jérôme Crittin; Christopher Bauser; Bettina Rohde; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2009-06-26

Review 8.  Update on mucormycosis pathogenesis.

Authors:  Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

9.  Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Authors:  Donna M MacCallum; Alix Coste; Françoise Ischer; Mette D Jacobsen; Frank C Odds; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.